Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Calcium antagonists and Raynaud's phenomenon]

E Hachulla1, B Devulder

  • 1Service de Médecine Interne, Hôpital Claude Huriez, CHRU, Lille.

Therapie
|November 1, 1993
PubMed
Summary

Raynaud's phenomenon, a common condition affecting 10% of people, involves episodic vasospasm. Calcium channel blockers are effective treatments for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Annual symposium on difficult diagnosis in internal medicine: "Les Printemps de la médecine interne"].

La Revue de medecine interne·2014
Same author

Tubercular adenitis and Evans' syndrome.

Lupus·2006
Same author

[Cloned amyloidosis].

La Revue de medecine interne·2005
Same author

[Hypertrophic myopathy due to muscular metastasis of a signet cell adenocarcinoma of the bladder].

La Revue de medecine interne·2004
Same author

[A real scheming!].

La Revue de medecine interne·2004
Same author

Large granular lymphocyte leukaemia associated with systemic sclerosis.

Rheumatology (Oxford, England)·2004

Area of Science:

  • Vascular Medicine
  • Pharmacology

Context:

  • Raynaud's phenomenon is a prevalent condition, affecting approximately 10% of the general population.
  • While often benign, it can be triggered by medications, occupational exposures, or underlying connective tissue diseases.

Purpose:

  • To review the epidemiology, pathophysiology, and treatment of Raynaud's phenomenon.
  • To highlight the role of calcium channel blockers in managing this condition.

Summary:

  • Raynaud's phenomenon involves episodic arteriolar vasospasm, with sympathetic nervous system hyperactivity and adrenergic receptor dysfunction implicated in its pathophysiology.
  • Calcium channel blockers have demonstrated significant efficacy in treating both primary and secondary Raynaud's phenomenon, particularly by inhibiting alpha 2-adrenoceptor mediated vascular responses.

Impact:

  • Provides an overview of Raynaud's phenomenon for clinicians and researchers.
  • Emphasizes the therapeutic potential of calcium channel blockers in managing vasospastic disorders.

Related Experiment Videos